Althea UK and Medipass Healthcare – two of the UK’s leading Managed Equipment Services (MES) companies – have announced they have merged operations and have been rebranded as Ergéa.
Ergéa will provide MES for: radiology, radiotherapy, endoscopy, cardiology, and surgical theatres, as well as providing vendor independent maintenance services for endoscopy, radiology and biomed equipment in the UK.
The CEO of Althea UK, David Rolfe, will continue as the CEO of Ergéa UK. The CEO of Medipass Healthcare, John Muolo, will continue leading the Radiotherapy MES operations of Ergéa UK as the Executive Vice President and Director of Strategic Relationships.
"Combining the capabilities of Althea and Medipass Healthcare in the UK allows us to bring added value to customers by offering a broader range of solutions. This enhanced capability has already enabled the first new MES contract to be signed, which is a direct result of the expertise, experience, and customer relationships of the combined teams," said David Rolfe. “Our new name, Ergéa, derives from a blending of words in the Greek language and translates as ‘working for health’. The name captures our ambition to help bring better healthcare and innovations to patients.”
Ergéa UK is part of the Ergéa Group, the leading cancer care and diagnostic imaging services platform in Europe. In Germany and Italy, Ergéa provides diagnosis and care at its own outpatient clinics as well as supports private and public hospitals through embedded clinical services and MES. The majority owner of Ergéa is DWS, one of the world’s leading asset and infrastructure managers, on behalf of one of its European infrastructure funds.
John Muolo commented: "Being part of the Ergéa group enables us to gain and leverage insights from clinical activities across Europe to enhance our MES offering in the UK. We are excited about the opportunities ahead and continue to prioritise the wellbeing of patients in everything we do."
Ergéa’s service delivery, customer support, staff and workshop locations will remain the same and not be affected by the merger.
